Analyst Ratings For ARS Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for ARS Pharmaceuticals (NASDAQ:SPRY) over the past three months, with a recent average price target of $25.0. The company has shown significant revenue growth and maintains a strong financial position despite challenges in asset utilization.

September 09, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ARS Pharmaceuticals has received mixed analyst ratings, with a recent average price target of $25.0. The company has demonstrated significant revenue growth and maintains a strong financial position, though it faces challenges in asset utilization.
The mixed analyst ratings, with a recent average price target increase, suggest a positive short-term outlook for ARS Pharmaceuticals. The company's significant revenue growth and strong financial position further support a likely upward price movement, despite challenges in asset utilization.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100